文献速递腹部MR

单发肝细胞癌根治性切除术后预后:聚焦术前钆塞酸增强MRI的LI-RADS靶样表现

Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
PubMed 文献 · Korean J Radiol · 2021-07-26

本研究回顾性纳入242例单发HCC(≤5 cm)根治性切除患者,术前均行钆塞酸增强MRI。按LI-RADS分类,LR-M伴环形动脉期高强化者术后总生存和无复发生存显著低于LR-4/5,且为独立预后因素,提示进一步细分LR-M有助于预测术后预后。

要点

  • 术前MRI LI-RADS LR-M伴环形动脉期高强化提示单发HCC切除术后预后较差。
  • LR-M不伴环形动脉期高强化者术后生存与LR-4/5无显著差异。
  • 肿瘤大小也是术后总生存和无复发生存的独立影响因素。

核心结论

  • LR-M伴环形动脉期高强化是单发HCC根治性切除术后总生存和无复发生存的独立不良预后因素。
  • 按环形动脉期高强化有无进一步细分LR-M有助于预测术后预后。
  • MVI影像特征与术后生存无独立关联。

研究设计与样本

  • 回顾性研究,纳入242例(190例男性,平均年龄57.1岁)单发HCC(≤5 cm)并接受根治性切除及术前钆塞酸增强MRI的患者。
  • 研究时间为2012年1月至2015年3月,评估LI-RADS分类、LR-M按环形动脉期高强化亚组及MVI影像特征。
  • 分析总生存、无复发生存及其相关因素。

关键影像表现/征象

  • 242个HCC中,190个(78.5%)为LR-4/5,25个(10.3%)为LR-M伴环形动脉期高强化,27个(11.2%)为LR-M不伴环形动脉期高强化。
  • LR-M伴环形动脉期高强化组5年总生存率68.0%、无复发生存率45.8%,均显著低于LR-4/5组的93.9%和66.8%(均p<0.05)。
  • LR-M不伴环形动脉期高强化组5年总生存率91.3%、无复发生存率80.2%,与LR-4/5组无显著差异(均p>0.05)。

诊断标准与关键数值

  • LR-M伴环形动脉期高强化 vs LR-4/5:总生存HR 5.48(p=0.002),无复发生存HR 2.09(p=0.042)。
  • 肿瘤大小每增加1 cm:总生存HR 6.04(p=0.009),无复发生存HR 1.77(p=0.014)。
  • MVI影像特征与总生存和无复发生存均无独立关联(p>0.05)。

临床应用与阅片要点

  • 阅片时应关注LI-RADS LR-M亚型,特别是环形动脉期高强化,以辅助术后预后分层。
  • 对于LR-M伴环形动脉期高强化的单发HCC患者,术后应加强随访监测。

局限性

  • 回顾性单中心研究,样本量有限,结论需外部验证。
  • 未报告MVI影像特征的具体定义及评估一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the prognostic implications of preoperative magnetic resonance imaging (MRI) features of hepatocellular carcinoma (HCC) with a focus on those with targetoid appearance based on the Liver Imaging Reporting and Data System (LI-RADS), as well as known microvascular invasion (MVI) features.

MATERIALS AND METHODS: This retrospective study included 242 patients (190 male; mean age, 57.1 years) who underwent surgical resection of a single HCC (≤ 5 cm) as well as preoperative gadoxetic acid-enhanced MRI between January 2012 and March 2015. LI-RADS category was assigned, and the LR-M category was further classified into two groups according to rim arterial-phase hyperenhancement (APHE). The imaging features associated with MVI were also assessed. The overall survival (OS), recurrence-free survival (RFS), and their associated factors were evaluated.

RESULTS: Among the 242 HCCs, 190 (78.5%), 25 (10.3%), and 27 (11.2%) were classified as LR-4/5, LR-M with rim APHE, and LR-M without rim APHE, respectively. LR-M with rim APHE (vs. LR-4/5; hazard ratio [HR] for OS, 5.48 [p = 0.002]; HR for RFS, 2.09 [p = 0.042]) and tumor size (per cm increase; HR for OS, 6.04 [p = 0.009]; HR for RFS, 1.77 [p = 0.014]) but not MVI imaging features (p > 0.05) were independent factors associated with OS and RFS. Compared to the 5-year OS and RFS rates in the LR-4/5 group (93.9% and 66.8%, respectively), the LR-M with rim APHE group had significantly lower rates (68.0% and 45.8%, respectively, both p < 0.05), while the LR-M without rim APHE group did not significantly differ in the survival rates (91.3% and 80.2%, respectively, both p > 0.05).

CONCLUSION: Further classification of LR-M according to the presence of rim APHE may help predict the postoperative prognosis of patients with a single HCC.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Moon JY, Min JH, Kim YK, et al. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI. Korean J Radiol. 2021. PMID: 34402243. doi:10.3348/kjr.2020.1428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。